{"id":"NCT02337062","sponsor":"Acacia Pharma Ltd","briefTitle":"Phase IIIb Study of APD421 in Combination as PONV Prophylaxis","officialTitle":"Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2015-01-13","resultsPosted":"2017-08-04","lastUpdate":"2019-03-20"},"enrollment":1147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["PONV"],"interventions":[{"type":"DRUG","name":"APD421","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"APD421 + standard anti-emetic","type":"EXPERIMENTAL"},{"label":"Placebo + standard anti-emetic","type":"PLACEBO_COMPARATOR"}],"summary":"A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).","primaryOutcome":{"measure":"Number of Participants With Complete Response","timeFrame":"24 hours after the end of surgery","effectByArm":[{"arm":"APD421 5mg + Standard Anti-emetic","deltaMin":330,"sd":null},{"arm":"Placebo + Standard Anti-emetic","deltaMin":268,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":25,"countries":["United States","France","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":572},"commonTop":["Nausea","Procedural Pain"]}}